Company intelligence / Profile preview
CTCELLS
Daegu, Daegu Metropolitan City, South Koreactcells.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
CTCELLS is developing advanced cancer diagnostics and immunotherapies. Their liquid biopsy platform enables high-efficiency isolation and analysis of circulating tumor cells, while their MBP-enhanced NK cell therapies and bispecific antibody programs are designed to improve efficacy and safety in cancer treatment. No published late-stage clinical results as of the latest information.
- Therapeutic areas
- Oncology
- Modalities
- Bispecific antibodiesMembrane-bound protein (MBP) technologyNatural Killer (NK) cell therapyLiquid biopsy diagnostics
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on CTCELLS.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CTCELLS.